share_log

Moderna | 8-K: Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates

Moderna | 8-K: Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates

Moderna | 8-K：Moderna公布2024年第一季度财务业绩并提供业务最新情况
美股sec公告 ·  05/02 06:33
Moomoo AI 已提取核心信息
On May 2, 2024, Moderna, Inc. reported its financial results for the first quarter ending March 31, 2024, with revenues of $167 million, a significant decrease from $1.9 billion in the same period the previous year. The decline was attributed to reduced sales of its COVID-19 vaccine, Spikevax. Despite a GAAP net loss of $1.2 billion and a diluted EPS of $(3.07), Moderna is preparing for the launches of its RSV vaccine and updated Spikevax formula, with expected product sales of approximately $4 billion for 2024. The company has initiated three new clinical studies in partnership with Merck for cancer treatments and is advancing three new vaccine programs toward Phase 3 clinical trials. Moderna's cash position decreased to $12.2 billion from $13.3 billion at the end of 2023, mainly due to research and development expenses and operating activities. The company reaffirmed its 2024 financial framework, expecting revenue of about $4 billion from its respiratory franchise and projecting year-end cash and investments to be approximately $9 billion.
On May 2, 2024, Moderna, Inc. reported its financial results for the first quarter ending March 31, 2024, with revenues of $167 million, a significant decrease from $1.9 billion in the same period the previous year. The decline was attributed to reduced sales of its COVID-19 vaccine, Spikevax. Despite a GAAP net loss of $1.2 billion and a diluted EPS of $(3.07), Moderna is preparing for the launches of its RSV vaccine and updated Spikevax formula, with expected product sales of approximately $4 billion for 2024. The company has initiated three new clinical studies in partnership with Merck for cancer treatments and is advancing three new vaccine programs toward Phase 3 clinical trials. Moderna's cash position decreased to $12.2 billion from $13.3 billion at the end of 2023, mainly due to research and development expenses and operating activities. The company reaffirmed its 2024 financial framework, expecting revenue of about $4 billion from its respiratory franchise and projecting year-end cash and investments to be approximately $9 billion.
2024年5月2日，Moderna, Inc.公布了截至2024年3月31日的第一季度财务业绩，收入为1.67亿美元，较去年同期的19亿美元大幅下降。下降归因于其 COVID-19 疫苗Spikevax的销量减少。尽管GAAP净亏损为12亿美元，摊薄后的每股收益为3.07美元（3.07美元），但Moderna仍在为其呼吸道合胞病毒疫苗和更新的Spikevax配方的推出做准备，预计2024年的产品销售额约为40亿美元。公司已与默沙东合作启动了三项新的癌症治疗临床研究，并正在推进三项新的疫苗计划，以进行三期临床试验。Moderna的现金状况从2023年底的133亿美元下降至122亿美元，这主要是由于研发费用和运营活动所致。该公司重申了其2024年的财务框架，预计其呼吸特许经营权的收入约为40亿美元，并预计年终现金和投资约为90亿美元。
2024年5月2日，Moderna, Inc.公布了截至2024年3月31日的第一季度财务业绩，收入为1.67亿美元，较去年同期的19亿美元大幅下降。下降归因于其 COVID-19 疫苗Spikevax的销量减少。尽管GAAP净亏损为12亿美元，摊薄后的每股收益为3.07美元（3.07美元），但Moderna仍在为其呼吸道合胞病毒疫苗和更新的Spikevax配方的推出做准备，预计2024年的产品销售额约为40亿美元。公司已与默沙东合作启动了三项新的癌症治疗临床研究，并正在推进三项新的疫苗计划，以进行三期临床试验。Moderna的现金状况从2023年底的133亿美元下降至122亿美元，这主要是由于研发费用和运营活动所致。该公司重申了其2024年的财务框架，预计其呼吸特许经营权的收入约为40亿美元，并预计年终现金和投资约为90亿美元。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息